Ardelyx Reports Strong 2025 Revenue And Outlook
Ardelyx, Inc. reported preliminary unaudited product revenue results for fourth quarter and full-year 2025, saying Ibsrela revenue rose 73% year-over-year and Xphozah sales increased. The company announced a Phase 3 program for Ibsrela in chronic idiopathic constipation, initiation of next-generation NHE3 inhibitor RDX10531, and guidance anticipating continued growth and Ibsrela peak sales exceeding $1 billion, with patent protection through 2041.
Scoring Rationale
Solid company updates and Phase 3 start drive relevance, but limited industry-wide novelty and low AI/DS relevance.
Practice with real Health & Insurance data
90 SQL & Python problems · 15 industry datasets
250 free problems · No credit card
See all Health & Insurance problemsStep-by-step roadmaps from zero to job-ready — curated courses, salary data, and the exact learning order that gets you hired.
Sources
- Read OriginalArdelyx, Inc. (ARDX) Reports Strong 2025 Revenue Growth, Updates 2026 Outlookinsidermonkey.com
